Abstracts tagged "kinase and rheumatoid arthritis"

Abstract Number: 1319 • 2017 ACR/ARHP Annual Meeting
TAS05567 Is a Novel Potent and Selective Spleen Tyrosine Kinase Inhibitor That Attenuates Disease Severity in Animal Models of Autoimmune Diseases
Hiroaki Hayashi, Ryuusuke Kaneko, Manabu Tayama, Shunsuke Demizu, Daichi Akasaka, Hiroki Irie, Aki Kawagishi, Yoshio Ogino, Teruhiro Utsugi, Eiji Sasaki and Yoshikazu Iwasawa, TAIHO PHARMACEUTICAL CO., LTD., Tsukuba, Japan
Background/Purpose: Spleen tyrosine kinase (Syk) is a non-receptor cytoplasmic tyrosine kinase. B-cell receptor (BCR) and Fc receptor-mediated syk signaling pathways lead to activation of several…
Abstract Number: 1454 • 2016 ACR/ARHP Annual Meeting
Combination of the SYK Inhibitor, GS-9876, with a JAK Inhibitor Increases Efficacy in a Chronic Rat Model of Collagen-Induced Arthritis
Julie Di Paolo¹, David Alonzo², Christian Franci³, Terry Gentzler¹, Li Li⁴, Bernard Murray⁵ and Jim Zheng⁵, ¹Biology, Gilead Sciences, Foster City, CA, ²FPD, Gilead Sciences, Foster City, CA, ³Biology, Gilead Sciences, Foster, CA, ⁴Gilead Sciences, South San Francisco, CA, ⁵DMPK, Gilead Sciences, Foster City, CA
Background/Purpose: Here we demonstrate that 1) the single agent activity of GS-9876 is efficacious in a late stage rat model of collagen-induced arthritis (CIA);…
Abstract Number: 1106 • 2015 ACR/ARHP Annual Meeting
Efficacy of Abbv-105, a Selective and Irreversible Inhibitor of Bruton’s Tyrosine Kinase (BTK), in Multiple Models of Inflammation
Christian Goess¹, Candace Graff², Ting Ting Zhang², Gregory Preston², Richard McCarthy¹, Matthew Perham¹, Jacqueline Loud¹, Christopher M. Harris¹, Sara Murdock¹, Erik Sampson³, Michael Hoemann⁴, Michael Friedman⁴, Robert Talanian³, Jeremy Edmunds⁴ and Andrew Long¹, ¹Immunology Pharmacology, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ²DMPK, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ³AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ⁴Chemistry, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA
Background/Purpose: Bruton’s Tyrosine Kinase (BTK) is a non-receptor tyrosine kinase required for intracellular signaling pathways downstream of several key immunoreceptors, including the B cell receptor,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].